Green tea consumption and liver disease: A systematic review

Liver International

Volumn 28, Issue 7, 2008, Pages 990-996

  Jin, Xi ^a   Zheng, Ruo Heng ^b   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HANGZHOU RED CROSS HOSPITAL   (China)

Author keywords

Green tea consumption; Liver disease; Systematic review

Indexed keywords

CATECHIN; GREEN TEA EXTRACT; POLYPHENOL;

BIOMEDICINE; CASE CONTROL STUDY; CHINA; CLINICAL TRIAL; COHORT ANALYSIS; DATA BASE; DIETARY INTAKE; DRUG EFFICACY; EMBASE; FATTY LIVER; HUMAN; JAPAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PROTECTION; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; UNITED STATES;

CAMELLIA SINENSIS; HUMANS; LIVER DISEASES; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEA;

EID: 47949091916     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01776.x     Document Type: Review

References (41)

1. Xu J, Yang F, An X, Hu Q. Anticarcinogenic activity of selenium-enriched green tea extracts in vivo. J Agric Food Chem 2007; 55: 5349-53.
2. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006; 45: 309-19.
3. Metro D, Muraca U, Manasseri L. Role of green tea in oxidative stress prevention. Clin Ter 2006; 157: 507-10.
4. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: Potential mechanism for its lipid-lowering effect. J Nutr Biochem 2007; 18: 179-83.
5. Li RW, Douglas TD, Maiyoh GK, Adeli K, Theriault AG. Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model. J Ethnopharmacol 2006; 104: 24-31.
6. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292: E1378-87.
7. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: A meta-analysis. Arch Intern Med 2007; 167: 626-34.
8. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and colorectal cancer risk: A meta-analysis of epidemiologic studies. Carcinogenesis 2006; 27: 1301-9.
9. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and breast cancer risk: A meta-analysis of epidemiological studies. Carcinogenesis 2006; 27: 1310-5.
10. Seely D, Mills EJ, Wu P, Verma S, Guyatt GH. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: A systematic review and meta-analysis. Integr Cancer Ther 2005; 4: 144-55.
11. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001; 154: 495-503.
12. Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA. Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. Int J Epidemiol 2001; 30: 353-62.
13. Abe K, Suzuki T, Ijiri M, Koyama Y, Isemura M, Kinae N. The anti-fibrotic effect of green tea with a high catechin content in the galactosamine-injured rat liver. Biomed Res 2007; 28: 43-8.
14. Abe K, Ijiri M, Suzuki T, Taguchi K, Koyama Y, Isemura M. Green tea with a high catechin content suppresses inflammatory cytokine expression in the galactosamine-injured rat liver. Biomed Res 2005; 26: 187-92.
15. Arteel GE, Uesugi T, Bevan LN, et al. Green tea extract protects against early alcohol-induced liver injury in rats. Biol Chem 2002; 383: 663-70.
16. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: A meta-analysis. Gastroenterology 2007; 132: 1740-5.
17. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 1998; 52: 377-84.
18. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: A systematic review. J Bone Miner Res 2007; 22: 447-57.
19. Zhang ZQ, Liu QF, Huang YR, Wu YD. An epidemiologic trial of using green tea to prevent liver cancer (in Chinese). GuangXi Prev Med 1995; 1: 5-7.
20. Xu YC, Shen HB, Niu JY, Shen J. An intervention trial with green tea on high risk population of primary liver cancer (in Chinese). Cancer Res Prev Treatment 1998; 25: 223-5.
21. Yuan YB, Wang ZQ, Hu XX, Jiang QW. Cohort study of drinking green tea on liver disease (in Chinese). Pract Prev Med 2005; 12: 1016-8.
22. Shen HB, Xu YC, Shen J, Niu JY. The relationship between habit of drinking green tea and primary liver cancer: A case control study (in Chinese). Chin J Behav Med Sci 1996; 5: 88-9.
23. Xiao JP, Shen XN, Wu M, Lu RF. Epidemiologic survey on the association between green tea intake and fatty liver disease (in Chinese). China Public Health 2002; 18: 385-7.
24. Mu LN, Zhou XF, Ding BG, Wang RH. Study on the protective effect of green tea on gastric, liver and esophageal cancer (in Chinese). Chin J Prev Med 2003; 37: 171-3.
25. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995; 310: 693-6.
26. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928-36.
27. Mou NZ, Ren GL, Mou LH, Lu CT. Research on the influence of catechin on fatty liver disease (in Chinese). Shandong J Traditional Chin Med 1998; 17: 55-6.
28. Mu D, Yu JX, Li D. Observation on the therapeutic effect in the treatment of 26 patients with fatty liver by tea pigment capsules (in Chinese). J Norman Bethune Univ Med Sci 1997; 23: 528-30.
29. Demeule M, Michaud-Levesque J, Annabi B, et al. Green tea catechins as novel antitumor and antiangiogenic compounds. Curr Med Chem Anticancer Agents 2002; 2: 441-63.
30. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334-50.
31. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881-6.
32. Hasegawa R, Chujo T, Sai-Kato K, Umemura T, Tanimura A, Kurokawa Y. Preventive effects of green tea against liver oxidative DNA damage and hepatotoxicity in rats treated with 2-nitropropane. Food Chem Toxicol 1995; 33: 961-70.
33. Cai YJ, Ma LP, Hou LF, Zhou B, Yang L, Liu ZL. Antioxidant effects of green tea polyphenols on free radical initiated peroxidation of rat liver microsomes. Chem Phys Lipids 2002; 120: 109-17.
34. Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992; 21: 510-9.
35. Murase T, Nagasawa A, Suzuki J, Hase T, Tokimitsu I. Beneficial effects of tea catechins on diet-induced obesity: Stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 2002; 26: 1459-64.
36. Tokimitsu I. Effects of tea catechins on lipid metabolism and body fat accumulation. Biofactors 2004; 22: 141-3.
37. Xiao J, Lu R, Shen X, Wu M. Green tea extracts protected against carbon tetrachloride-induced chronic liver damage and cirrhosis. Zhonghua Yu Fang Yi Xue Za Zhi 2002; 36: 243-6.
38. Li YM, Zhang XG, Zhou HL, Chen SH, Zhang Y, Yu CH. Effects of tea polyphenols on hepatic fibrosis in rats with alcoholic liver disease. Hepatobiliary Pancreat Dis Int 2004; 3: 577-9.
39. Zhang XG, Yu CH, Qing YE, Zhang Y, Chen SH, Li YM. Effect of tea polyphenol on liver fibrosis in rats and related mechanism. Zhongguo Zhong Yao Za Zhi 2003; 28: 1070-2.
40. Lee MJ, Wang ZY, Li H, et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 1995; 4: 393-9.
41. Luo H, Tang L, Tang M, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: Modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27: 262-8.